Used in targeted cancer therapies, particularly in research and development of treatments for solid tumors such as breast, ovarian, and endometrial cancers. It functions by binding to DLK1 (Delta-like 1 homolog), a protein overexpressed in certain tumor cells, enabling precise targeting for antibody-drug conjugates (ADCs). This antibody serves as a critical reference standard in immunoassays, helping evaluate the binding affinity and specificity of experimental DLK1-targeting therapeutics. It supports quality control in biopharmaceutical development and aids in the validation of diagnostic tools for detecting DLK1 expression in tumor tissues.